Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals

Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals

Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of infectious diseases 2014-01, Vol.10 (4), p.179-183
Hauptverfasser: Gonçalves Rossi, Livia Maria, Rahal, Paula
Format: Artikel
Sprache:eng
Schlagworte:
Hepatitis C virus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 183
container_issue 4
container_start_page 179
container_title American journal of infectious diseases
container_volume 10
creator Gonçalves Rossi, Livia Maria
Rahal, Paula
description Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.
doi_str_mv 10.3844/ajidsp.2014.179.183
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1680436854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1680436854</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-8498e7b0841703b8a588ab40dc7076b4d9d3aa8e72d0b34321c2f2d3b30fbbeb3</originalsourceid><addsrcrecordid>eNotkD1PwzAURS0EEqXwC1g8siQ8-zmJM1YttEhFSIiP0bITB1y1SbAdJP49CWU6d7j3DoeQawYpSiFu9c7VoU85MJGyokyZxBMyY1kmkxwFnP5lTHIOeE4uQtgBoOQcZuR9ZaOtouta2jV0Y3sdXXSBLumb80Ogzza4EHUb6eMwIVDX0vhpqfV6WqycH-d0MV60H3TRRvftvN6HS3LWjLBX_5yT1_u7l-Um2T6tH5aLbVJhWcREilLawoAUrAA0UmdSaiOgrgoociPqskatxwqvwaBAzire8BoNQmOMNTgnN8ff3ndfgw1RHVyo7H6vW9sNQbFcgsBcZmKs4rFa-S4EbxvVe3fQ_kcxUJNGddSoJo1q1KhGjfgLdGZnjA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1680436854</pqid></control><display><type>article</type><title>Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gonçalves Rossi, Livia Maria ; Rahal, Paula</creator><creatorcontrib>Gonçalves Rossi, Livia Maria ; Rahal, Paula</creatorcontrib><description>Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.</description><identifier>ISSN: 1553-6203</identifier><identifier>EISSN: 1558-6340</identifier><identifier>DOI: 10.3844/ajidsp.2014.179.183</identifier><language>eng</language><subject>Hepatitis C virus</subject><ispartof>American journal of infectious diseases, 2014-01, Vol.10 (4), p.179-183</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-8498e7b0841703b8a588ab40dc7076b4d9d3aa8e72d0b34321c2f2d3b30fbbeb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gonçalves Rossi, Livia Maria</creatorcontrib><creatorcontrib>Rahal, Paula</creatorcontrib><title>Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals</title><title>American journal of infectious diseases</title><description>Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.</description><subject>Hepatitis C virus</subject><issn>1553-6203</issn><issn>1558-6340</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNotkD1PwzAURS0EEqXwC1g8siQ8-zmJM1YttEhFSIiP0bITB1y1SbAdJP49CWU6d7j3DoeQawYpSiFu9c7VoU85MJGyokyZxBMyY1kmkxwFnP5lTHIOeE4uQtgBoOQcZuR9ZaOtouta2jV0Y3sdXXSBLumb80Ogzza4EHUb6eMwIVDX0vhpqfV6WqycH-d0MV60H3TRRvftvN6HS3LWjLBX_5yT1_u7l-Um2T6tH5aLbVJhWcREilLawoAUrAA0UmdSaiOgrgoociPqskatxwqvwaBAzire8BoNQmOMNTgnN8ff3ndfgw1RHVyo7H6vW9sNQbFcgsBcZmKs4rFa-S4EbxvVe3fQ_kcxUJNGddSoJo1q1KhGjfgLdGZnjA</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Gonçalves Rossi, Livia Maria</creator><creator>Rahal, Paula</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>20140101</creationdate><title>Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals</title><author>Gonçalves Rossi, Livia Maria ; Rahal, Paula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-8498e7b0841703b8a588ab40dc7076b4d9d3aa8e72d0b34321c2f2d3b30fbbeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Hepatitis C virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonçalves Rossi, Livia Maria</creatorcontrib><creatorcontrib>Rahal, Paula</creatorcontrib><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>American journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonçalves Rossi, Livia Maria</au><au>Rahal, Paula</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals</atitle><jtitle>American journal of infectious diseases</jtitle><date>2014-01-01</date><risdate>2014</risdate><volume>10</volume><issue>4</issue><spage>179</spage><epage>183</epage><pages>179-183</pages><issn>1553-6203</issn><eissn>1558-6340</eissn><abstract>Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.</abstract><doi>10.3844/ajidsp.2014.179.183</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1553-6203
ispartof American journal of infectious diseases, 2014-01, Vol.10 (4), p.179-183
issn 1553-6203
1558-6340
language eng
recordid cdi_proquest_miscellaneous_1680436854
source EZB-FREE-00999 freely available EZB journals
subjects Hepatitis C virus
title Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A58%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20Hepatitis%20C%20Virus%20Resistant%20Mutants%20in%20the%20era%20of%20Direct%20Acting%20Antivirals&rft.jtitle=American%20journal%20of%20infectious%20diseases&rft.au=Gon%C3%A7alves%20Rossi,%20Livia%20Maria&rft.date=2014-01-01&rft.volume=10&rft.issue=4&rft.spage=179&rft.epage=183&rft.pages=179-183&rft.issn=1553-6203&rft.eissn=1558-6340&rft_id=info:doi/10.3844/ajidsp.2014.179.183&rft_dat=%3Cproquest_cross%3E1680436854%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1680436854&rft_id=info:pmid/&rfr_iscdi=true